BIOVANCE 3L Ocular
Ocular surface disease and ocular surgery (e.g., pterygium)
Key Facts
About DefEYE
DefEYE is an emerging player in the ophthalmic medical device sector, specializing in decellularized biologic matrices. The company's core innovation is its BIOVANCE 3L Ocular product, which is positioned as the only decellularized basement membrane (DBM) available for ocular surface reconstruction, featuring room-temperature storage and multiple size options. Led by CEO Rob Sambursky, MD, DefEYE aims to transform therapeutic approaches in eye care by providing integrated solutions that improve surgical outcomes and manage ocular surface diseases. The company is in the commercial stage with its first product, targeting a significant market opportunity in corneal and conjunctival repair.
View full company profile